What is the current price and volume for IDIA.SW stock?

IDIA.SW stock is trading pre-market at **CHF 3.08** with volume **1,976,535**. The day range is **CHF 2.97–3.13** and the 50-day average price is **CHF 3.68**.

What target does Meyka AI give for IDIA.SW stock?

Meyka AI's forecast model projects a 12‑month target of **CHF 5.60**, implying about **81.70%** upside from **CHF 3.08**. Forecasts are model-based projections and not guarantees.

What are the main risks for IDIA.SW stock investors?

Primary risks for IDIA.SW stock are negative operating cash flow **CHF -0.64 per share**, binary clinical outcomes, and a negative book value per share **CHF -4.58**. Regulatory setbacks would likely pressure the share price.

How does IDIA.SW stock compare to its Healthcare peers?

IDIA.SW stock trades at a price-to-sales **2.85** and negative PE, versus Swiss Healthcare average PE **~26.77**. Idorsia’s valuation reflects early-stage pipeline risk versus larger drugmakers with stable earnings.

CH Stocks

IDIA.SW Idorsia Ltd (SIX) CHF3.08 pre-market 21 Mar 2026: most active, B+ outlook

ByDanny Kontos March 21, 2026

IDIA.SW stock opened pre-market at CHF 3.08 on 21 Mar 2026 with volume 1,976,535, making Idorsia Ltd one of the most active names on the SIX today. Traders are watching the biotech’s current price versus its 50-day average CHF 3.68 and its year high CHF 4.85. The combination of heavy turnover, negative EPS -0.52, and a recent technical pullback sets up a short-term trading story. Below we break down valuation, technical signals, pipeline catalysts, and Meyka AI’s grade and model forecast to frame potential entry points and risks for investors.